Liraglutide Shows CV Benefit: Clinical Perspectives on the LEADER Trial

Slides:

Advertisements

Similar presentations

Insulin therapy.

Advertisements

New Insulin Formulations

Tresiba- insulin degludec

Insulin degludec (Tresiba®)

Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.

What's New in Basal Insulin for Diabetes

Mastery of Medicine in Diabetes Management Video Roundtable

Recommendation In people with clinical cardiovascular disease in whom glycemic targets are not met, a SGLT2 inhibitor with demonstrated cardiovascular.

Short-, Intermediate-, Long-Acting Insulins

Updates and Perspectives in Diabetic Dyslipidemia

Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.

Applying Data to Practice

CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?

Patient Case 1 Peggy Peggy Interactive Case Question.

Special Consideration in Insulin Therapy

Faster-Acting Insulins

Insulin Safety know your insulins! There are many! Humalog® Mix25 Humalog® Mix50 Humulin® I Humulin® M3 Humulin® S Humalog® U-100 Humalog® U-200.

Modern Strategies for Basal Insulin Use in T2D

Cardiovascular (CV) Safety and Severe Hypoglycemia Benefit of Insulin Degludec vs Insulin Glargine U100 in Older Patients (≥65 years) with Type 2 Diabetes.

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Insulin Innovation.

Updates on Outcomes for Novel T2D Therapies

Obesity and Dyslipidemia: How Would You Treat?

How Early Should Basal Insulin Be Used in T2D Management?

Novel Concentrated Insulins: What Benefits and for Which Patients?

SGLT2 Inhibitors in the Modern Era: Why and Where?

Examining CV Effects of Basal Insulin Therapy

Iron Deficiency Anemia

Emerging CVOT Data and Clinical Application

Looking Beyond Glucose Control: Multifactorial Management of Type 2 Diabetes.

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

Emerging Basal Insulins for Diabetes

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

Faster-Acting Insulins

Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?

Integrated Diabetes Care: How Can We Make the Best Use of New Technology?

A Journal Club on Lipid Management:

Novel Basal Insulin Formulations in the Modern Era of T2D Management

Insulin Innovation.

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.

Type 2 Diabetes Management: Where Are We Heading in Our Efforts to Control CV Risk?

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?

LEADER One Year On.

Iron Deficiency Anemia

GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?

Novel Approaches to T1D Management

Antihyperglycemic Therapy

CV Outcomes and Adherence With GLP-1 RAs

Program. Basal Insulin in the Modern Era The CDE's Role in Improving Utilization and Outcomes.

Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?

CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?

Insulin Innovation.

Updates From ACC.

Insulin in Diabetes Management: Effective Patient Selection Is Key

Glucose Management and Statin Therapy

Hypoglycemia Is BAD.

Improving Effective Basal Insulin Use in Clinical Practice

Are All Novel Insulins Proven to Be Equally Safe?

Glucose Management and Statin Therapy

Emerging Combination Injectable Therapy A New Era in Diabetes Care

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.

Statin Selection in Patients With Pre-Diabetes: Case Considerations

INSULINS Dr.R.Sajjad december INSULINS Dr.R.Sajjad december 2018.

What's New in Oral Combination Therapy for Type 2 Diabetes?

Expert Perspectives.

An insulin simplification regimen: from multiple injections to once-daily long-acting (basal) insulin plus noninsulin agents. *Basal insulins: glargine.

Emerging Basal Insulins for Diabetes

Fresh perspectives ON BASAL Insulins in diabetes care

The Challenge of Insulin Titration

Presentation transcript:

T2D Updates From ADA 2016: New Data on Injectable Therapy and Impact on Practice

Liraglutide Shows CV Benefit: Clinical Perspectives on the LEADER Trial

Semaglutide*

New Efficacy and Safety Data for Ultra-Rapid-Acting Aspart

Unmet Need: Ultra-Rapid-Acting Insulins

Faster-Acting Insulin Aspart* Onset of Action

Future Role of Rapid-Acting Insulin

New Efficacy and Safety Data for Ultra-Rapid-Acting Aspart

Unmet Need: Ultra-Rapid-Acting Insulins

Faster-Acting Insulin Aspart* Onset of Action

Future Role of Rapid-Acting Insulin

Lower Nocturnal Hypoglycemia Risk With Insulin Glargine U300 in Type 2 Diabetes

Concentrated Insulin Glargine U300

U300 Glargine Post Hoc Patient-Level Meta-Analysis

Clinical Use of Glargine U300

Reduced Hypoglycemia With Insulin Degludec in Patients With Type 1 or Type 2 Diabetes

SWITCH 1

SWITCH 2

Clinical Use of Degludec

Closing Remarks